Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

1. Ultrasound AI for Cardiac
Imaging
A Better Way to Analyze the Whole Heart
OTC: VPTDF & TSX-V: VPT

2. Symbol: TSX-V: VPT & OTC: VPTDF
Capital Structure
Shares Outstanding 127M
Shares Fully Diluted 148M
Recent share price CDN$.32
52-Week Range CDN$.07-.325
Market Cap ~CDN$40M
Insider ownership
(FD)
6%
Public Float
ownership
Debt
Cash
Liquidity
94%
None
2 years
CDN$600,000/day
TSXV:VPT
2

3. An AI imaging company with proprietary 4
quadrant cardiac analysis technology
Overview
US-FDA approved + EU, Canada and China
Entering high growth phase with goal to place
80-100 units by mid-2022
Clear path to liquidity providing attractive
shareholder ROI
Placed in first 11 clinical sites and 11 more
placements in process
TSXV:VPT
3

4. Market Need
Although the 2D echocardiogram is the most commonly-used
cardiac diagnostic tool world-wide, it does NOT:
 obtain accurate and reliable volumes for any heart chamber
 measure right ventricle (RV) volume & ejection fraction in children
 provide a standard metric for all cardiac patients
 work on difficult to scan (e.g. obese) patients
Prior to VMS+3.0, this degree of detail has required a referral for an MRI
scan, which is:
 limited in it’s accessibility - an issue in most communities
 significantly more costly than ultrasound
 less efficient
 requires contrast media and often sedation of patients

5. VMS+ 3.0™ vs MRI
Factor MRI VMS+ 3.0™
Scan time 60 – 120 minutes 5 minutes
Patient movement Motionless Full movement allowed
Patient preparation Sedation and injection of
contrast media
None
Image availability 1 – 2 days Immediately
Analysis Radiologist (MD) Technologist
Analysis time 15 – 45 minutes 5 minutes
Reader Radiologist – 15 minutes Cardiologist – 1 minute
Workflow
1st appt with cardiologist
2nd appt for MRI (months)
3rd appt with cardiologist
Scan and analysis during
1st appointment with
cardiologist
Capital Cost $2 – 4 million $50,000
TSXV:VPT
5

6. Ventripoint VMS+ 3.0 System
Processes all standard 2D echocardiograms to generate MRI equivalent 3D cardiac metrics
Interfaces with all
standard echocardiogram
2D cardiac ultrasound
machines (GE, Siemens,
Philips, Toshiba)
provides Cardiologists
confidence in their diagnosis
10 year $30M development
of 3rd generation AI
software has now elevated
2D echocardiogram to MRI
level accuracy
The Solution

7. VMS+3.0 takes 2D Echocardiogram
(Cardiac Ultrasound) Images and…

8. …provides 3D cardiac measurements
equivalent to MRI

9. VMS+3.0 delivers standardized cardiac metrics
for all patients and their physicians

10. Milestones Achieved

11. Market Opportunity
Ventripoint has identified key market segments to drive sales
 Congenital Heart Defects (CHD)
 Standard-of-care guidelines require patient follow-up every
three months for life
 Pulmonary Hypertension (PAH)
 Significant patient population
 Cardiotoxic Effects of Chemotherapy
 20 – 30% of oncology patients experience heart damage
 COVID-19 Patients
 Virus causes heart damage in a high percentage of patients
 Companion Animals
 10% of 100M dogs in USA have heart issues
* In each case, Ventripoint can provide clinically
important data faster and at less expense than MRI
TSXV:VPT
11

12. Clinical Need
HEART DISEASE IS THE LEADING CAUSE OF
DEATH FOR BOTH MEN AND WOMEN
WORLDWIDE
CARDIAC MEASUREMENTS ARE
CRITICAL TO ASSESS HEART DISEASE
1.4 BILLION SPENT ON NEW
ECHOCARDIOGRAM MACHINES EACH YEAR
200 BILLION SPENT ON CARDIOVASCULAR
DISEASE IN US ANNUALLY

13. Key Recent Placements
MD Anderson Cancer Center
Houston, TX – October 2020
Erasmus-Sophia University Medical Center
The Netherlands - September 2020
Peter Munk
Cardiac Centre-
UHN
Toronto,
Canada -
November
2020
TSXV:VPT
13
King’s College Hospital London,
UK - Dec 2020

14. Market Entry w/KOL’s
 Key Opinion Leaders (KOL) per market segment to evaluate
system and present/publish at major medical conferences
 Host Regional Ventripoint-moderated webinars featuring
KOLs with VMS+3.0 experience. Two webinars planned in
1Q21 – one each for North America and Europe
 Publish multiyear experience of major heart centre using
VMS to monitor CHD in children
 Association-sponsored webinars
 American Adult Congenital Heart Disease Association
 Will increase awareness as marketed to physician
databases

15. Installed Ultrasound Base VMS+3.0
Opportunity
Application USA Canada Europe Total
Oncology 10,000 1,000 15,000 26,000
Pulmonary
Hypertension
2,000 200 3,000 5,500
Congenital 4,000 400 6,000 11,000
Total 16,000 1,600 24,000 41,600
• VMS+3.0 can be integrated with any common ultrasound system
• USD$50,000 per placement imputes a $2B+ market opportunity

16. Revenue Model
List price of USD $50,000 per unit
 $5K annual licence fee generates recurring revenue
 Patient patch consumable per procedure
Sales focused on 41,600 unit installed base of ultrasound
systems
Pay-per-use model to reduce barriers to system acquisition
lease for $15K/year (first 200 cases free)
$50/case thereafter
US customers able to access existing reimbursement code (76377):
 $98 - $200 per case
 Rapid breakeven (75-150 cases)
TSXV:VPT 16

17. Early Sales Traction
 11 sites completed and 11 sites in process
 Hospital committed placements include:
 Can – 5 sites completed/2 additional sites in process
 US – 1 site completed/4 additional sites in process
 UK – 1 site completed and 3 sites in process
 Europe – 1 site completed/2 sites in process
 China – 3 sites completed
 VPT anticipates that multiple units will be purchased regularly
by each hospital that uses the VMS+3.0.
TSXV:VPT 17

18. Companion Animals
• Initiated collaboration with Veterinary School at
North Carolina Sate University to validate use of
VMS+3.0 on dogs.
• Initial studies show existing databases work
correctly and reconstructions accurate
• 37% of households in USA have adopted a pet in
last 12 months (Bank of America Study)
• Over 100M companion dogs in USA and 10% have
heart disease
• 30,000 veterinary practices in USA

19. Exit Opportunities
 Acquisition by multinational ultrasound
company such as Philips, Siemens, GE,
Samsung
 Ventripoint will be of interest when it
reaches 80 – 100 installed sites
 Recent acquisition of TomTech by Philips for
more than USD$100M
 Acquisition by service provider such as
McKesson, Circle or PIA
* Growing sales, recurring revenues and 80%
margins are attractive

20. • Mr. Hirson is a seasoned executive with over 20 years of experience in commercializing medical devices and
managing product development, manufacturing operations, regulatory and quality assurance
• Previously as Vice President Engineering at Sonosite and was part of the acquisition by FUJIFILM , Mr. Hirson led a
development team to commercialize novel ultrasound technology from prototype to market success in
cardiovascular, cancer and other areas of pre-clinical research that also resulted in ground-breaking clinical
applications
Desmond Hirson, Chief Technology Officer
• Dr. Adams is known as a scientist, innovator, entrepreneur and venture financier. Using his medical and
engineering knowledge he has spent 40 years developing and commercializing medical discoveries related to the
heart and blood vessels. The products which he has commercialized have been implanted or used to support life in
300 million people in the last 35 years. Dr Adams was named a Technology Pioneer by the World Economic Forum,
attended the Davos meeting and featured in Time magazine worldwide.
George Adams PhD, CEO
Experienced Leadership Team
Alvira Macanovic, PhD, Senior Director, Operations, Regulatory Affairs & Quality Assurance
• Dr. Macanovic has over 10 years of experience in pharmaceutical and medical device related industries, where she
has worked with researchers, start-ups, SMEs, and multi-national companies to commercialize technologies in
multiple therapeutic areas
• At a prior start-up focused on medical imaging, Dr. Macanovic oversaw all aspects of the regulatory affairs/quality
operations for the successful launch of the company’s products in Canada, the United States, and China
• Mr. McPhedran brings over 30 years of capital equipment sales experience in the medical industry including both
medical imaging and laboratory diagnostics
• As Sales Director for Siemens Healthcare, Mr. McPhedran lead a dynamic sales team responsible for the sale of the
full portfolio of diagnostic imaging equipment and thin client network solutions for advanced post processing of
imaging data in Western Canada with an annual target of over 35M per year
Dave McPhedran, Global Sales Director

21. Key Investment Considerations
 $2B+ market opportunity
 Substantially de-risked – product is developed,
regulatory approvals in hand and sales successfully
under way
 Recent acquisitions suggest valuations of greater
than USD$100M very feasible
 Proven team has accomplished similar plans
multiple times in the past
 Current valuation of ~USD$30M enables excellent
return

22. Thank You
For further information contact:
Dr. George Adams – CEO
gadams@ventripoint.com
Ventripoint Diagnostics Ltd.
2 Sheppard Avenue East, Suite 605
Toronto Ontario M2N 5Y7 Canada
(519) 803-6937
Investor Relations:
Clay Chase @ Torrey Hills Capital
(858) 456-7300
cc@sdthc.com
Website: www.ventripoint.com
OTC: VPTDF & TSX-V: VPT